Orexo Receives US Patent for Its Nasal Epinephrine Powder Product OX640

Orexo Receives US Patent for Its Nasal Epinephrine Powder Product OX640

By, Admin 19 April 2024

Overview

Orexo AB, a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs, has announced that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX drug delivery platform.

USPTO Patent

  • In August 2023, the USPTO granted the first patent for OX640 in the US, providing protection until May 2041. 
  • The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term, now extending until November 2042. 
  • Orexo has multiple patent applications filed on a global basis and expects to continuously strengthen the patent portfolio for OX640.

Word from CEO: Orexo AB

  • Nikolaj Sørensen, president and CEO, said: Once again, I am pleased with the USPTO recognising the inventiveness of our OX640 product and the AmorphOX technology. This is the eighth patent based on the technology, underscoring its uniqueness and value. 
  • In parallel, we continue to broaden the applications of AmorphOX by testing the technology with new substances, which is expected to lead to more patents. The extended exclusivity for OX640 build additional long-term value and improves the attractiveness for potential partners for commercialization in the US market.

About OX640

  • OX640 is based on AmorphOX and its powder-based technology provides excellent chemical and physical stability. 
  • In addition to providing allergic patients with a more convenient, needle-free alternative to auto-injectors currently on the market, an epinephrine product that provides greater flexibility in relation to how it can be handled and stored should provide significant benefits to patients and healthcare systems worldwide.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!